摘要
姜黄素是亚洲香料中的一种黄色色素,是姜黄根茎的天然多酚成分。类姜黄素成分包括姜黄素、去甲氧基姜黄素 (DMC) 和双去甲氧基姜黄素 (BDMC)。先前的研究根据临床前和临床评估将姜黄素确定为一种安全药物,并且类姜黄素已被美国食品和药物管理局 (FDA) 批准为“公认安全”(GRAS)。本综述收集并总结了姜黄素相互作用的临床和临床前研究,重点是姜黄素和姜黄素类似物对微粒体 CYP450 酶(I 期代谢)的 mRNA 和蛋白质水平的影响及其与毒物、药物和药物探针的相互作用.使用各种科学数据库中的关键字进行文献搜索,包括 Web of Science、Scopus、PubMed 和 Google Scholar。回顾了关于姜黄素和姜黄素类似物对微粒体酶活性影响的研究,包括对人类和实验动物的口服、局部和全身治疗,以及来自体外研究的研究。综合起来,数据确定了各种研究之间的一些不一致的结果。研究结果表明姜黄素及其类似物对 CYP450 酶有显着抑制作用。然而,当姜黄素和姜黄素类似物与毒物和其他药物以及药物探针共同给药时,这种效果通常是不同的。我们从这篇综述中得出结论,当食用姜黄素和姜黄素类似物时,应考虑草药-药物相互作用。
关键词: 草药-药物相互作用、药代动力学、I 相代谢、微粒体酶、CYP 酶、姜黄素。
Current Medicinal Chemistry
Title:Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Volume: 28 Issue: 34
关键词: 草药-药物相互作用、药代动力学、I 相代谢、微粒体酶、CYP 酶、姜黄素。
摘要: Curcumin, a yellow pigment in Asian spice, is a natural polyphenol component of Curcuma longa rhizome. Curcuminoid components include curcumin, demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC). Previous studies established curcumin as a safe agent based on preclinical and clinical evaluations and curcuminoids have been approved by the US Food and Drug Administration (FDA) as “Generally Recognized as Safe” (GRAS). The present review collects and summarizes clinical and preclinical studies of curcumin interactions, with an emphasis on the effect of curcumin and curcumin analogs on the mRNA and protein levels of microsomal CYP450 enzymes (phase I metabolism) and their interactions with toxicants, drugs and drug probes. The literature search was conducted using keywords in various scientific databases, including Web of Science, Scopus, PubMed, and Google Scholar. Studies concerning the impact of curcumin and curcumin analogs on microsomal enzyme activity are reviewed and include oral, topical, and systemic treatment in humans and experimental animals, as well as studies from in vitro research. When taken together, the data identified some inconsistent results between various studies. The findings showed significant inhibition of CYP450 enzymes by curcumin and its analogs. However, such effects are often differed when curcumin and curcumin analogs were coadministered with toxicant and other drugs and drug probes. We conclude from this review that herb-drug interactions should be considered when curcumin and curcumin analogs are consumed.
Export Options
About this article
Cite this article as:
Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies, Current Medicinal Chemistry 2021; 28 (34) . https://dx.doi.org/10.2174/0929867328666210329123449
DOI https://dx.doi.org/10.2174/0929867328666210329123449 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Pathology Associated Memory Deficits in Swedish Mutant Genome-Based Amyloid Precursor Protein Transgenic Mice
Current Aging Science Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Evidence-Based Management of Infertile Couples with Repeated Implantation Failure Following IVF
Current Women`s Health Reviews An Efficient Approach for Diagnosis System of Cervical Cancer Using Image Fusion to Prevent Earlier Death in Women
Current Medical Imaging Malignancy Risk in Systemic Lupus: Recent Research and Ongoing Challenges
Current Rheumatology Reviews Evaluation of Anticancer, Antibacterial and Antioxidant Properties of a Medicinally Treasured Fern Tectaria coadunata with its Phytoconstituents Analysis by HR-LCMS
Anti-Cancer Agents in Medicinal Chemistry Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review
Current Drug Targets Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Current Drug Targets Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Inhibitory Effects of Novel SphK2 Inhibitors on Migration of Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Overexpression of miR-340-5p Inhibits Skin Fibroblast Proliferation by Targeting Kruppel-like Factor 2
Current Pharmaceutical Biotechnology Cry1A Proteins are Cytotoxic to HeLa but not to SiHa Cervical Cancer Cells
Current Pharmaceutical Biotechnology Physicochemical Characterization of Curcumin Loaded Chitosan Nanoparticles: Implications in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Current Medicinal Chemistry Hypoxic Radiosensitizers and Hypoxic Cytotoxins in Radiation Oncology
Current Medicinal Chemistry - Anti-Cancer Agents Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Preface
Current Pharmaceutical Design